5,386 Shares in Celgene Co. (CELG) Purchased by KCS Wealth Advisory
KCS Wealth Advisory acquired a new stake in shares of Celgene Co. (NASDAQ:CELG) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 5,386 shares of the biopharmaceutical company’s stock, valued at approximately $562,000.
Several other hedge funds and other institutional investors also recently modified their holdings of CELG. BlackRock Inc. raised its holdings in shares of Celgene by 5.7% in the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Celgene by 3.1% in the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Celgene by 11.5% in the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after buying an additional 1,546,673 shares during the last quarter. FMR LLC raised its holdings in shares of Celgene by 5.9% in the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after buying an additional 697,250 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Celgene by 3.3% in the second quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock valued at $1,439,025,000 after buying an additional 349,974 shares during the last quarter. 78.10% of the stock is owned by institutional investors.
A number of research analysts recently issued reports on the company. Mizuho reaffirmed a “buy” rating and issued a $128.00 price target on shares of Celgene in a report on Sunday, February 4th. Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. Cantor Fitzgerald reiterated a “hold” rating and issued a $112.00 price objective on shares of Celgene in a research report on Monday, January 29th. SunTrust Banks reiterated a “buy” rating and issued a $139.00 price objective (up from $127.00) on shares of Celgene in a research report on Friday, January 26th. Finally, Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 price objective for the company in a research report on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $130.35.
Celgene Co. (CELG) opened at $91.51 on Tuesday. The stock has a market capitalization of $69,583.77, a PE ratio of 13.48, a PEG ratio of 0.66 and a beta of 1.49. Celgene Co. has a 12-month low of $88.32 and a 12-month high of $147.17. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The company’s revenue for the quarter was up 16.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.61 EPS. equities research analysts predict that Celgene Co. will post 7.68 earnings per share for the current fiscal year.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.